**Product Details**

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

<table>
<thead>
<tr>
<th>Suggested Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
</tbody>
</table>

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

**Target Species**

Viral

**Product Form**

Inactivated Measles virus - liquid

**Preparation**

Measles virus, Edmonston strain, cultured in Vero cells. Optimally infected cells are disrupted in culture fluids. The suspension is clarified and concentrated by crossflow ultrafiltration. The antigen preparation is inactivated using gamma radiation, which primarily damages viral genetic material.

**Buffer Solution**

Minimum Essential Medium

**Preservative Stabilisers**

None present

**Approx. Protein Concentrations**

Total protein concentration 2.26 mg/ml.

**Product Information**

Native Measles Virus preparation contains a high concentration of virus and viral components. The preparation also contains some cellular material suspended in tissue culture medium.

The Measles virus is a highly contagious single-stranded RNA virus that is mostly spread via the respiratory system. It may be passed via aerosol droplets from coughs or through contact with infected bodily fluids. It causes measles, a disease characterised by fever, cough, runny nose, red eyes and a rash. Most patients with uncomplicated measles will recover without antiviral treatment, however, some patients may develop diarrhoea, corneal ulceration, pneumonia or encephalitis. Complications are more likely in adults. In developed countries, most children are immunised against measles by the age of 18 months, as part of the three-part MMR (measles, mumps and rubella) vaccine.
Activity
This product has been rendered inactive by standard procedures. However this material should still be handled as infectious and should be disposed of appropriately.

Instructions For Use
PIP013 should be sonicated immediately before use to ensure the preparation is uniform. The product may be used in a variety of immunoassay formats or may be further purified to meet the requirements of a particular assay format.

References

Storage
Store at -70°C.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the protein.

Guarantee
18 months from date of despatch

Health And Safety Information
Material Safety Datasheet documentation #10286 available at:

Regulatory
For research purposes only